Bharat Biotech Covid Vaccine Becomes First Indian Vaccine To Get Panel Nod
The Central Drugs Standard Control Organisation (CDSCO) panel on Saturday recommended granting approval for restricted emergency use of Bharat Biotech s indigenous Covid vaccine.
PTI 02 January 2021 Twitter PTI 2021-01-02T18:40:31+05:30 Bharat Biotech Covid Vaccine Becomes First Indian Vaccine To Get Panel Nod outlookindia.com 2021-01-02T22:05:58+05:30
Also read
An expert panel of India s central drug authority on Saturday recommended granting permission for the restricted use of Bharat Biotech-developed indigenous COVID-19 vaccine Covaxin in an emergency situation, especially in the context of infection by mutant strains, officials said.
SEC recommends Bharat Biotech’s Covaxin for emergency use
SECTIONS
Last Updated: Jan 02, 2021, 09:49 PM IST
Share
Synopsis
The Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.
Bharat Biotech s Covaxin gets Subject Expert Committee (SEC) approval for emergency use
2,743,475.0
An expert panel of India s central drug authority on Saturday recommended granting permission for restricted use of Bharat Biotech-developed indigenous COVID-19 vaccine Covaxin in emergency situation, especially in the context of infection by mutant strains, officials said.
The recommendation for Bharat Biotech s vaccine came a day after the panel cleared the Serum Institute of India s emergency use athorisation application for the Oxford-AstraZeneca vaccine Covishield. This paves the way for the roll-out of at least two vaccines in India in the coming days, while two more are in advance stages of development. At a press conference in Ne
An expert panel of India s central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said. Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts and analysis subsequent to Friday s review meeting, a source said.
India clears Covaxin, ‘certain conditions’ follow Bharat Biotech vaccine gets emergency use authorisation from CDSCO
Covaxin, the anti-coronavirus vaccine developed indigenously by India’s Hyderabad-based Bharat Biotech, has received restricted emergency use permission, with certain conditions, from an expert panel of India s central drug authority on Saturday, sources said.
Covaxin has been developed by the Hyderabad-based company in collaboration with the Indian Council of Medical Research (ICMR).
The Union Health Ministry on Saturday also confirmed that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to the Serum Institute of Institute (SII) for restricted emergency use of Covishield in India, subject to multiple regulatory conditionalities.
NEW DELHI: An expert panel of India s central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed Covid-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford Covid-19 vaccine, sources said.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts and analysis subsequent to Friday s review meeting, a source said.